vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Principal Financial Group (PFG). Click either name above to swap in a different company.
Principal Financial Group is the larger business by last-quarter revenue ($750.8M vs $598.7M, roughly 1.3× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 0.3%, a 40.6% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs 4.0%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -58.3%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Principal Financial GroupPFGEarnings & Financial Report
Principal Financial Group, Inc. (PFG) is an American global financial investment management and insurance company headquartered in Des Moines, Iowa, United States.
EXEL vs PFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $750.8M |
| Net Profit | $244.5M | $1.9M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | — |
| Net Margin | 40.8% | 0.3% |
| Revenue YoY | 5.6% | 4.0% |
| Net Profit YoY | 74.8% | 783.0% |
| EPS (diluted) | $0.89 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $750.8M | ||
| Q4 25 | $597.8M | $4.6B | ||
| Q3 25 | $568.3M | $3.7B | ||
| Q2 25 | $555.4M | $3.7B | ||
| Q1 25 | $566.8M | $3.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | $539.5M | $3.0B | ||
| Q2 24 | $637.2M | $4.3B |
| Q1 26 | $244.5M | $1.9M | ||
| Q4 25 | $193.6M | $517.0M | ||
| Q3 25 | $184.8M | $213.8M | ||
| Q2 25 | $159.6M | $406.2M | ||
| Q1 25 | $139.9M | $48.1M | ||
| Q4 24 | — | $905.4M | ||
| Q3 24 | $118.0M | $-220.0M | ||
| Q2 24 | $226.1M | $353.1M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 28.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 43.3% | — |
| Q1 26 | 40.8% | 0.3% | ||
| Q4 25 | 32.4% | 11.3% | ||
| Q3 25 | 32.5% | 5.8% | ||
| Q2 25 | 28.7% | 11.1% | ||
| Q1 25 | 24.7% | 1.3% | ||
| Q4 24 | — | 19.1% | ||
| Q3 24 | 21.9% | -7.3% | ||
| Q2 24 | 35.5% | 8.2% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $2.30 | ||
| Q3 25 | $0.65 | $0.95 | ||
| Q2 25 | $0.55 | $1.79 | ||
| Q1 25 | $0.47 | $0.21 | ||
| Q4 24 | — | $3.92 | ||
| Q3 24 | $0.40 | $-0.95 | ||
| Q2 24 | $0.77 | $1.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | — |
| Total Assets | $2.8B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $4.4B | ||
| Q3 25 | $791.1M | $5.1B | ||
| Q2 25 | $1.0B | $3.7B | ||
| Q1 25 | $1.1B | $3.9B | ||
| Q4 24 | — | $4.2B | ||
| Q3 24 | $1.2B | $6.2B | ||
| Q2 24 | $1.0B | $4.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.9B | ||
| Q3 25 | — | $3.9B | ||
| Q2 25 | — | $3.9B | ||
| Q1 25 | — | $4.3B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | — | $3.9B |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $11.9B | ||
| Q3 25 | $2.0B | $11.7B | ||
| Q2 25 | $2.1B | $11.4B | ||
| Q1 25 | $2.2B | $11.2B | ||
| Q4 24 | — | $11.1B | ||
| Q3 24 | $2.3B | $11.2B | ||
| Q2 24 | $2.1B | $11.0B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $341.4B | ||
| Q3 25 | $2.7B | $334.5B | ||
| Q2 25 | $2.8B | $323.1B | ||
| Q1 25 | $2.9B | $313.0B | ||
| Q4 24 | — | $313.7B | ||
| Q3 24 | $3.0B | $322.9B | ||
| Q2 24 | $2.8B | $308.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.39× | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $1.7B | ||
| Q3 25 | $49.0M | $1.0B | ||
| Q2 25 | $211.4M | $811.9M | ||
| Q1 25 | $240.3M | $977.3M | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $271.3M | $1.1B | ||
| Q2 24 | $119.5M | $1.4B |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | — | ||
| Q1 25 | $236.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 3.37× | ||
| Q3 25 | 0.27× | 4.70× | ||
| Q2 25 | 1.32× | 2.00× | ||
| Q1 25 | 1.72× | 20.32× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | 4.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PFG
Segment breakdown not available.
